Cancer Research Targets Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Cancer Research 68, 346, January 15, 2008. doi: 10.1158/0008-5472.CAN-07-1183
© 2008 American Association for Cancer Research
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Adriaenssens, E.
Right arrow Articles by Hondermarck, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Adriaenssens, E.
Right arrow Articles by Hondermarck, H.

Priority Reports

Nerve Growth Factor Is a Potential Therapeutic Target in Breast Cancer

Eric Adriaenssens1, Elsa Vanhecke1, Pasquine Saule3, Alexandra Mougel3, Adeline Page2, Rodrigue Romon1, Victor Nurcombe4, Xuefen Le Bourhis1 and Hubert Hondermarck1

1 INSERM U908, Institut National de la Sante et de la Recherche Medicale, "Growth factor signaling in breast cancer cells. Functional Proteomics", IFR-147 and 2 Mass Spectrometry Facility, IFR-147, University Lille 1, 3 Centre National de la Recherche Scientifique UMR8527, Institute of Biology, Lille, France; and 4 Institute of Molecular and Cell Biology, Singapore, Singapore

Requests for reprints: Hubert Hondermarck, INSERM U908, Institut National de la Sante et de la Recherche Medicale, University Lille 1, Batiment SN3, 59655 Villeneuve d'Ascq, Lille, France. Phone: 33-320-43-40-97; E-mail: Hubert.hondermarck{at}univ-lille1.fr.

We show here that nerve growth factor (NGF), the prototypic neurotrophin, can be targeted in breast cancer to inhibit tumor cell proliferation, survival, and metastasis. Analysis of a series of biopsies revealed widespread expression of NGF in the majority of human breast tumors, with anti-NGF immunoreactivity concentrated in the epithelial cancer cells. Moreover, immunodeficient mice xenografted with human breast cancer cells and treated with either anti-NGF antibodies or small interfering RNA against NGF displayed inhibited tumor growth and metastasis. Such treatments directed against NGF induced a decrease in cell proliferation with a concomitant increase in apoptosis of breast cancer cells and an inhibition of tumor angiogenesis. Together, these data indicate that targeting NGF in breast cancer may have therapeutic ramifications. [Cancer Res 2008;68(2):346–51]




This article has been cited by other articles:


Home page
 Am. J. Pathol.Home page
H. Hondermarck
Nerve Growth Factor: The Dark Side of the Icon
Am. J. Pathol., April 1, 2008; 172(4): 865 - 867.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2008 by the American Association for Cancer Research.